Share：
Share this content in WeChat
X
[Chinese][PDF]80274
• Review •
Research advancements of single-domain antibody in molecular imaging of prostate cancer
ZHONG Jin-man  REN Jing  HUAN Yi 

DOI:10.3969/j.issn.1674-8034.2015.09.016.


[Abstract] In the present, prostate cancer still remains one of the most common malignancy afflicting elderly men and its morbidity and mortality significantly increase with population aging, which makes prostate cancer remain a major global cancer problem. Earlier diagnosis and treatment is an essential strategy for better survival rate in prostate cancer. Single-domain antibody (SdAb) is an antigen-specific, variable fragment of camelid heavy chain-only antibody. The smaller size, better stability and ability to recognize and combine with unique epitope specifically as an affinity reagent have made SdAb a useful class of biomolecular for study and diagnostic and therapeutic application in malignancy. In this summary, we review the current relevant studies on SdAb for prostate cancer in molecular imaging, which may provide a new train of thought for future study and clinical application.
[Keywords] Prostatic neoplasms；Molecular diagnostic techniques；Prostate-specific antigen；Diagnostic imaging

ZHONG Jin-man Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi-an 710032, China

REN Jing* Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi-an 710032, China

HUAN Yi Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi-an 710032, China

*Correspondence to: Ren J, E-mail: jrenmm@126.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work was part of the Program of Natural Science Foundation of China No. 81370039, 81220108011
Received  2015-05-30
Accepted  2015-07-22
DOI: 10.3969/j.issn.1674-8034.2015.09.016
DOI:10.3969/j.issn.1674-8034.2015.09.016.

[1]
Cronin KA, Ries LA, Edwards BK. The surveillance, epidemiology, and end results (SEER) program of the national cancer institute. Cancer, 2014, 120, 23(Suppl): 3755-3757.
[2]
Chakravarty R, Goel S, Cai W. Nanobody: the magic bullet for molecular imaging? Theranostics, 2014, 4(4): 386-398.
[3]
Cassidy PJ, Radda GK. Molecular imaging perspectives. JR Soc Interface, 2005, 2(3): 133-144.
[4]
Desmyter A, Spinelli S, Roussel A, et al. Camelid nanobodies: killing two birds with one stone. Curr Opin Struct Biol, 2015, 32C: 1-8.
[5]
Perez JM, Renisio JG, Prompers JJ, et al. Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry, 2001, 40(1): 74-83.
[6]
Smolarek D, Bertrand O, Czerwinski M. Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine? Postepy Hig Med Dosw (Online), 2012, 66: 348-358.
[7]
Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res, 2004, 64(8): 2853-2857.
[8]
Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, et al. Nanobodies and their potential applications. Nanomedicine (Lond), 2013, 8(6): 1013-1026.
[9]
Xavier C, Vaneycken I, D’ Huyvetter M, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med, 2013, 54(5): 776-784.
[10]
Huang L, Gainkam LO, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol, 2008, 10(3): 167-175.
[11]
Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol, 2007, 77(1): 13-22.
[12]
Lilja H, Oldbring J, Rannevik G, et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest, 1987, 80(2): 281-285.
[13]
Huang L, Reekmans G, Saerens D, et al. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens Bioelectron, 2005, 21(3): 483-490.
[14]
Saerens D, Kinne J, Bosmans E, et al. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem, 2004, 279(50): 51965-51972.
[15]
Heston WD. Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase. Urologe A, 1996, 35(5): 400-407.
[16]
Troyer JK, Beckett ML, Wright GJ. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer, 1995, 62(5): 552-558.
[17]
Abdel-Nabi H, Wright GL, Gulfo JV, et al. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol, 1992, 10(1): 45-54.
[18]
Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol, 2001, 7(1): 27-37.
[19]
Evazalipour M, Tehrani BS, Abolhassani M, et al. Camel heavy chain antibodies against prostate-specific membrane antigen. Hybridoma (Larchmt), 2012, 31(6): 424-429.
[20]
Evazalipour M, D’ Huyvetter M, Tehrani BS, et al. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Contrast Media Mol Imaging, 2014, 9(3): 211-220.
[21]
Zare H, Rajabibazl M, Rasooli I, et al. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells. Int J Biol Markers, 2014, 29(2): e169-e179.
[22]
Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, et al. A novel 111In-labeled anti-PSMA nanobody for targeted SPECT/CT imaging of prostate cancer. J Nucl Med, 2015, 56(7): 1094-1099.
[23]
Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist, 2002, 7, 4(Suppl): 31-39.
[24]
Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging, 2008, 35(1): 186-208.
[25]
Hernot S, Unnikrishnan S, Du Z, et al. Nanobody-coupled microbubbles as novel molecular tracer. J Control Release, 2012, 158(2): 346-353.
[26]
Oliveira S, van Dongen GA, Stigter-Van WM, et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging, 2012, 11(1): 33-46.
[27]
Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J, 2011, 25(7): 2433-2446.
[28]
Gainkam LO, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med, 2008, 49(5): 788-795.
[29]
Arbabi GM, Desmyter A, Wyns L, et al. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett, 1997, 414(3): 521-526.
[30]
Kijanka M, Warnders F, El Khattabi M, et al. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Eur J Nucl Med Mol Imaging, 2013, 40(11): 1718-1729.
[31]
Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol, 2008, 26(11): 1774-1777.
[32]
Kijanka M, Dorresteijn B, Oliveira S, et al. Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond), 2015, 10(1): 161-174.

PREV The clinical application and technology progress of high-resolution MRI in carotid intraplaque hemorrhage
NEXT ISMRM 23rd Annual Meeting: Review and Look Ahead
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn